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Abstract
Salmonellosis is one of the most important bacterial zoonotic diseases transmitted through
the consumption of contaminated food, with chicken and pig related products being key res-
ervoirs of infection. Although numerous studies on animal vaccination have been performed
in order to reduce Salmonella prevalence, there is still a need for an ideal vaccine. Here,
with the aim of constructing a novel live attenuated Salmonella vaccine candidate, we firstly
analyzed the impact of the absence of cyclic-di-GMP (c-di-GMP) in Salmonella virulence. C-
di-GMP is an intracellular second messenger that controls a wide range of bacterial pro-
cesses, including biofilm formation and synthesis of virulence factors, and also modulates
the host innate immune response. Our results showed that a Salmonellamultiple mutant in
the twelve genes encoding diguanylate cyclase proteins that, as a consequence, cannot
synthesize c-di-GMP, presents a moderate attenuation in a systemic murine infection
model. An additional mutation of the rpoS gene resulted in a synergic attenuating effect that
led to a highly attenuated strain, referred to as ΔXIII, immunogenic enough to protect mice
against a lethal oral challenge of a S. Typhimurium virulent strain. ΔXIII immunogenicity
relied on activation of both antibody and cell mediated immune responses characterized by
the production of opsonizing antibodies and the induction of significant levels of IFN-γ, TNF-
α, IL-2, IL-17 and IL-10. ΔXIII was unable to form a biofilm and did not survive under desic-
cation conditions, indicating that it could be easily eliminated from the environment. More-
over, ΔXIII shows DIVA features that allow differentiation of infected and vaccinated
animals. Altogether, these results show ΔXIII as a safe and effective live DIVA vaccine.
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Introduction
Salmonella remains a foodborne pathogen of rising concern to consumers and governments
worldwide. In Europe, Salmonella is the second most frequently reported cause of foodborne
outbreaks with known origin, with Salmonella enterica sv enteritidis (S. Enteridis) and Salmo-
nella enterica sv typhimurium (S. Typhimurium) being the two most commonly detected sero-
vars. The number of officially reported clinical cases of salmonellosis amounts to almost 90.000
according to the report of the European Food Safety Authority (EFSA) for the year 2014
(https://www.efsa.europa.eu/en/efsajournal/pub/4329), and the overall economic burden has
been estimated to be as high as 3 billion euros a year.
The fact that Salmonella gastroenteritis cases usually follow the consumption of contami-
nated basic food products such as poultry derivatives or pig meat, in combination with the
rapid spread of multidrug resistant Salmonella spp. triggered by the high-productivity-focused
model of animal breeding [1,2] has prompted the appearance of new policies aimed at the pre-
vention of Salmonella intake into the food chain. Thus, public health programs including
means such as the improvement of hygienic conditions in farms, the use of fodder supplements
and the execution of effective vaccination protocols are being gradually implemented. Many
Salmonella vaccines have been tested in poultry and swine, with varying degrees of success (for
review, see [3–5]). These can be divided into three categories: live-attenuated, inactivated and
subunit vaccines. As regards whole cell killed and subcellular vaccines, biosafety for both
human and farm animals is their main advantage. However, it is generally accepted that protec-
tion conferred by these last preparations is fairly modest when they are compared to vaccines
based on live attenuated Salmonella strains [6,7]. This assertion is supported by the potential of
live bacteria to activate both humoral and cellular adaptive immune responses [8] and by their
capacity to inhibit intestinal colonization during the “immunity gap” (period of time after neo-
natal vaccination when there is no longer sufficient maternal immunoglobulins to afford pro-
tection from infection but when there is still enough of this maternal protection to prevent the
young animal from mounting its own protective immune response) [9]. If other evidences like
the easiness of production and administration are considered, we obtain a scenario in which
the livestock industry calls for new live attenuated vaccines that display an improved balance
between attenuation (safety) and immunogenicity (efficacy).
Since the early 90´s, attenuation of Salmonella has been accomplished by the introduction
of mutations in aro genes and global regulators like PhoPQ, Crp or RpoS (for review, see [10]).
Other common attenuation strategies are based on auxotrophies raised by mutation of genes
involved in the synthesis of purines (purA, purEmutants) or in the metabolism of carbohy-
drates (galEmutants) [11,12] and on the elimination of determinants directly involved in infec-
tion establishment (e.g. pathogenicity islands, virulence plasmid, svp genes) [13,14]. Present-
day advances widening the knowledge about molecular mechanisms underlying Salmonella
virulence and the development of novel DNA engineering tools are currently leading to more
ambitious genetic approaches in the area of recombinant vaccines, and long-term visions
include Salmonella strains with regulated delayed attenuation in vivo and their use as antigen
carrier /delivery platforms [15]. Nevertheless, fairly curious is the fact that some of the strains
used as commercial vaccines, such as SG 9R, VacT or VacE, have been generated by passages
in the laboratory or by randommutagenesis and thus, the exact genetic basis of their attenua-
tion is largely unknown [10].
In our laboratory, we constructed a S. Enteritidis strain, called ΔXII, carrying mutations in
the twelve genes encoding GGDEF domain proteins and thus, incapable of synthesizing the
secondary messenger bis-(3–5)-cyclic dimeric GMP (c-di-GMP) [16]. This molecule is widely
recognized as a key regulator of bacterial biology, including the transition from a planktonic to
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a biofilm lifestyle and from the virulent state in acute infections to a less virulent state charac-
teristic of chronicity [17]. Furthermore, bacterial cyclic nucleotides have been recently involved
in modulating the innate immune response, leading to induction of type I interferons, via direct
binding to the eukaryotic Stimulator of Interferon Genes (STING) and to DDX41 [18–21]. Vir-
ulence assays with S. Enteritidis ΔXII showed that it was highly attenuated in orally and intra-
peritoneally infected BALB/c mice [16] and hence, this strain might be considered a potential
vaccine candidate. However, further work with ΔXII revealed that it contained an additional
chromosomal deletion of 16.8 kilobases that included the rpoS gene [22]. Since RpoS, which is
the master sigma factor during stationary phase and under a variety of stress conditions, plays
a critical role in Salmonella virulence [23], it was unclear whether the absence of c-di-GMP
played any role in virulence attenuation shown by ΔXII. To solve this and other questions
related to c-di-GMP signaling, a new ΔXII strain was generated, sequenced and confirmed to
only lack GGDEF proteins encoding genes [22].
Taking new ΔXII strain as a basis, the present work was planned with three main objectives:
(i) analyzing the contribution to Salmonella virulence of c-di-GMP signaling; (ii) confirming
the attenuation of a strain deficient in c-di-GMP signaling and RpoS with the aim of identifying
a genetic background that might lead to a novel attenuated Salmonella vaccine strain and, (ii)
assessing its potential use as an effective vaccine to combat gut and organ colonization by Sal-
monellae. Here, we report that total depletion of c-di-GMP in new ΔXII correlated with a mod-
erate loss of virulence in a murine model of infection. A ΔXII strain in which we also
performed a rpoSmutation led to a strain that we called ΔXIII, more attenuated than a single
rpoSmutant but still capable of eliciting a cellular/humoral balanced, long-lasting immune
response against a lethal oral-challenge of a S. Typhimurium virulent strain. Moreover, use of
ΔXIII enabled serological differentiation of vaccinated and infected mice due to the lack of anti-
bodies raised against the Salmonella specific GGDEF protein SEN4316 in vaccinated animals.
Materials and Methods
Ethics statement
Animal studies were performed in accordance with the European Community guiding in the
care and use of animals (Directive 2010/63/EU). Protocols were approved by the ethics com-
mittee of the Public University of Navarra (Comité de Ética, Experimentación Animal y Biose-
guridad of the Universidad Pública de Navarra) (approved protocol PI-004/11). Work was
carried out in the animal facility of the Instituto de Agrobiotecnología, Universidad Pública de
Navarra. Animals were housed under controlled environmental conditions with food and
water ad libitum. Mice were euthanized by CO2 inhalation followed by cervical dislocation and
all efforts were made to minimize suffering.
Bacterial strains and culture conditions
Bacteria were grown in LB broth and on LB agar with appropriate antibiotics at the following
concentrations: kanamycin (Km), 50 μg ml-1; ampicillin (Am), 100 μg ml-1; chloramphenicol
(Cm), 20 μg ml-1 and apramycin (Apr), 60 μg ml-1.
Bacterial strains used in this study are listed in S1 Table. S. Enteritidis 3934 (MIC-54) is a
wild type clinical isolate described in [24,25]. S. Enteritidis ΔXII (MIC-1324) is a multiple
mutant, derivative of 3934, carrying mutations in all genes encoding GGDEF domain proteins
and thus incapable of synthesizing c-di-GMP [22]. This multiple mutant was generated by a
markerless gene replacement method described in [16,22] and as a consequence, does not con-
tain any exogenous DNA. To compare the virulence of the wild type and ΔXII strain we used a
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ΔXII derivative (MIC-3664), resistant to kanamycin and tetracycline, that was generated in
[22].
S. Typhimurium CNM 143/09 (MIC-1201) is a clinical strain isolated from a patient that
suffered a pig meat borne gastroenteritis (Centro Nacional de Microbiología; Instituto de Salud
Carlos III).
To generate the single mutant ΔrpoS (MIC-2101), a PCR-generated linear DNA fragment in
combination with the helper plasmid pKOBEGA were used [25,26]. A selectable antibiotic
resistance gene was generated by PCR using oligonucleotides rpoS-Apra_fw (ctgaaagttcatgatt
taaatgaagacgcggaatttgatgagaacggagtagaggctttttcccatccaccggatcaatt) and rpoS-Apra_rv
(tgcgctcgttgagacgaagcatacggctgacgtcatcaaccggtttatccagttgctctgtccttgttagacattatttg) that
included 60-nt homology extensions for the targeted locus and 20-nt priming sequences for
the apramycin resistance gene as template from a freshly isolated colony of E. coliMC4100 F
´tet ΔtraD::aac [27]. Electroporation (25 μF, 200 O, 2.5 kV) was carried out according to the
manufacturer’s instructions (Bio-Rad) using 50 μl of cells and 1 to 5 μg of purified and dialyzed
(0.025 μm nitrocellulose filters; Millipore) PCR product. Shocked cells were added to 1 ml of
LB broth, incubated overnight at 30°C, and then spread on LB agar with Apr to select AprR
transformants after incubation at 30°C for 24 h. Mutants were then grown on LB broth with
Apr at 43°C for 24 h and incubated overnight on LB agar with Am at 30°C to test for the loss of
the helper plasmid.
To generate the vaccine candidate, S. Enteritidis ΔXIII (MIC-1330), the rpoS gene was
deleted in ΔXII (MIC-1324) strain as follows. DNA fragments corresponding to the upstream
(fragment AB) and downstream (fragment CD) regions of the rpoS gene were amplified with
the following oligonucleotides, with chromosomal DNA from strain S. Enteritidis 3934 as a
template. Primers RpoS_1´_Fw (gaatcgtatacaatcgccag) and RpoS_B_XhoI (ctcgaggctcctacccgt
gatcc) were used to amplify the AB fragment. Primers RpoS_C_XhoI (ctcgagttgtcaaaaaaaggc
cagtc) and RpoS_D_BglII (agatctaatctgccacaggtgatg) were used to amplify the CD fragment.
The PCR products were cloned in the pGEMt-easy vector (Promega), digested with NotI and
XhoI enzymes in the case of the AB fragment and XhoI and BglII enzymes in the case of the
CD fragment, and ligated in the same ligation mixture with the pKO3blue vector [16] digested
with NotI and BglII enzymes. The recombinant pKO3blue::AD vector was extracted from E.
coli XL1 Blue and electroporated into strain S. Enteritidis ΔXII. The following steps of integra-
tion and excision of the plasmid were performed as described previously [16]. As a result,
ΔXIII is a multiple mutant in all genes encoding GGDEF domain proteins and in rpoS and
does not contain any exogenous DNA.
Mice survival assays
Mice were acclimated for 7 days after arrival before the experiments were started. In the case of
oral infections, food and water were removed, twelve and two hours respectively, before the
administration of bacterial suspension. Mice were prefed with 20μl of 10% sodium bicarbonate
30 min before bacterial inoculation. Water and food were again supplied right after
inoculation.
For mice survival assays, eight-week-old female BALB/c mice (Charles River Laboratories)
were infected orally with 107 Salmonella wild type or mutant cells that had been grown over-
night in LB broth and resuspended in 100 μl of PBS. Mice survival was monitored for 20–28
days. Over the course of infection, mice were examined twice per day and a final disease score
was given to each mouse according to clinical signs observed as follows. No clinical signs (0);
mild clinical signs: ruffled fur (1); moderate clinical signs: ruffled fur plus, lethargy, hunched
posture and decreased activity (2); severe clinical signs: paresis, paralysis, tremor, shivers,
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ataxia, rigidity (3). When evident signs of disease (score 2 to 3) were observed, mice were
euthanized by CO2 inhalation followed by cervical dislocation.
Mice competitive infections
Infection studies were carried out with 8-week-old female BALB/c mice (Charles River Labora-
tories). Mice were inoculated intraperitoneally (i.p.) or intragastrically (i.g.) with 100 μl of bac-
teria suspended in phosphate-buffered saline (PBS; pH 7.4). The total bacteria inoculum was
2x104 cfu (i.p.) or 2x108 cfu (i.g.) of combined S. Enteritidis wild-type and mutant strains at a
ratio of 1:1. The cfu of each strain in the inoculum (input) was quantified by plating dilution
series on LB agar and using antibiotic resistance to distinguish between strains. Mice were
euthanized after 3 days (i.p.) or 5 days (i.g.), and dilution series of liver and spleen lysates were
plated on LB agar for enumeration of cfu (output), using antibiotic resistance to differentiate
strains. Values for competitive index (CI) were calculated as the ratio of wild type to mutant in
the output divided by that in the input, and the CI was expressed as log10 [28].
To compare the in vivo interaction of Salmonella strains with murine intestinal epithelial
cells, the ligated ileal loop co-infection model was used as described previously [25]. Values for
CI were calculated as described above.
Mice protection assay
Groups of seven 8-week-old female BALB/c mice were orally inoculated with 107 cfu of the
attenuated strains ΔXIII or ΔrpoS. One control group only received PBS. On day thirty-three
after immunization, immunized and control animals were intragastrically challenged with 106
cfu of virulent S. Typhimurium 143/09. Vaccinated and control mice were monitored daily to
assess clinical signs as described above. When evident signs of disease (score 2 to 3) were
observed, mice were opportunely euthanized by CO2 inhalation followed by cervical
dislocation.
Preparation of ΔXIII heat-killed lysate
The vaccine strain, ΔXIII, was cultured overnight at 37°C on LB agar plates. Bacteria were
resuspended in PBS and the OD600 was adjusted to 0.2 (1x10
8 cfu ml–1, based on viable cell
counts on LB agar). Bacteria were then incubated at 75°C in a water bath for 30 min. The effec-
tiveness of the inactivation was assessed by plating 100 μl of the suspension on LB agar, after
treatment.
Determination of antibody titers
Blood samples from the orbital vein of each mouse from the control and the ΔXIII-immunized
groups were collected before immunization and 14 and 28 days after immunization. Samples
were centrifuged and sera from each group were collected. Serum IgG and IgM were detected
by ELISA. For that, Nunc Maxisorp 96-well plates (Thermo Fisher Scientific, San Jose, CA)
were coated with 107 cfu of heat-killed ΔXIII bacteria and incubated at 4°C overnight. Plates
were then washed three times with PBS containing 0.05% Tween 20 (PBS-T; pH 7.4) and
blocked with 5% nonfat dried milk powder in PBS-T at room temperature for 1 h. After three
washes with PBS-T, immune mouse sera were serially diluted from an initial dilution of 1:20. A
100 μl volume of diluted sample was added to duplicate wells and incubated at 4°C overnight.
Wells were washed three times with PBS-T and 100 μl of horseradish peroxidase (HRP)-conju-
gated goat anti-mouse IgG, IgM (H+L) secondary antibody diluted 1:2500 (Thermo Scientific)
was added to each well. The plates were incubated for 1 h at room temperature and then
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washed three times. One hundred microliters of 3,30,5,50-Tetramethylbenzidine (TMB)
(Sigma-Aldrich) were added to each well and the absorbance at 405 nm was determined on an
ELISA reader. Endpoint titers were expressed as the reciprocal log2 values of the last positive
sample dilution. Absorbance readings higher than the mean plus two standard deviations of
preimmune serum baseline values were considered indicative of positive reactions.
Opsonophagocytosis uptake assay
The murine macrophage-like cell line J774.2 was grown in RPMI 1640 with 10% heat-inacti-
vated fetal bovine serum (FBS) and 1% Penicillin/Streptomicin (Lonza) at 37°C with 5% CO2.
Cells were seeded in 24-well tissue culture plates. Once in confluence (0.2 x 106 cells per well),
cells were washed with PBS, and medium without FBS was added 16 hours prior to the experi-
ment. Fourteen hours later, the medium was replaced by medium without antibiotics. 2 x 106
cfu of an overnight culture of S. Typhimurium143/09 was mixed with 10% of pooled immune
serum, pre-immune serum or PBS in 500 μl of Minimum Essential Medium Eagle (MEM) with
1% Bovine Serum Albumin (BSA) and complement (complement sera rabbit, Sigma-Aldrich).
After incubation at room temperature for 15 minutes, the mix was added to the monolayer
cells (multiplicity of infection of 10) and plates were incubated for 30 minutes at 37°C in 5%
CO2. To kill extracellular bacteria, cells were washed and incubated for 90 minutes with 500 μl
of RPMI 1640 containing 100 μg/ml gentamicin (Sigma-Aldrich). Cells were washed three
times with sterile PBS and lysed with 0.1% Triton X-100. The number of phagocytosed bacteria
was determined by plating serial dilutions of the lysates on LB agar and data were represented
as relative bacterial uptake of bacteria mixed with serum with respect to the uptake of bacteria
suspended in PBS, which was given a value of 1.0. Experiments were conducted in triplicate.
ELISPOT assay
The number of IFN-γ producing cells was measured by ELISPOT using a kit from BD-Bios-
ciences (BD Biosciences, San Diego, CA) according to the manufacturer´s instructions. Spleno-
cytes were harvested from individual mice 28 days after immunization. Ninety-six-well Multi-
Screen high protein binding Immobilon-P membrane plates (Millipore, Billerica, MA) were
coated with mouse anti–IFN-γ capture antibody, incubated overnight, and blocked for 2 h with
RPMI containing 10% fetal calf serum. Then, 1 x 106 splenic cells in 10% fetal calf serum-RPMI
were added to each well in triplicate and cultured in the presence or in the absence of 107 cfu of
heat-killed ΔXIII bacteria. Following overnight incubation, the plates were washed three times
with PBS and incubated with biotinylated anti-IFN-γ antibody for two hours. Wells were
washed three times and incubated with a solution of streptavidin-peroxidase for one hour.
Then, plates were washed and developed with freshly prepared 3,30-Diaminobenzidine (DAB)
solution. The reaction was stopped with distilled water and spots were counted using an ELI-
SPOT automated reader (CTL; Aalen, Germany).
Measurement of cytokine production by ELISA
1 x 106 splenic cells harvested from individual mice 28 days after immunization were co-cul-
tured with 107 cfu of heat-killed ΔXIII bacteria during 48 h. RPMI media was used as negative
control. IL-2, IL-10 and IL-17 released to the supernatant were measured by ELISA using spe-
cific kits from BD Biosciences (San Diego, CA) according to the manufacturer´s instructions.
Levels of IFN-γ and IL-5 in serum were determined using a Mouse Procarta Cytokine 2Plex
Assay (eBioscience). Levels of IL-10 in serum were determined with a Mouse IL-10 ELISA
Ready-SET-Go!1 kit (eBioscience).
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Flow cytometry analysis
Splenocytes (2x106/well) harvested from individual mice 28 days after immunization were
either stimulated with 106 and 107 cfu of heat-killed ΔXIII bacteria or rested unstimulated for
1h. Golgi-Plug and Golgi-Stop (BD Biosciences, San Diego, CA) were added and plates were
incubated for five hours. Then, cells were washed with staining buffer (PBS, 0.5% BSA, 2 mM
EDTA), surface stained with anti-CD8a-APC (53-6-7) and anti-CD4-FITC (RM45) monoclo-
nal antibodies (mAbs), fixed and permeabilized with Cytofix/Cytoperm solution (BD Biosci-
ences) and finally stained for intracellular cytokines with anti-TNF-α-PE-Cy7 (MP6-XT22)
and anti-IFN-γ-PE (XMG1,2) mAbs. All mAbs were from Biolegend (San Diego, CA). Dead
cells were excluded by FSC and SSC. Data were collected in a FACSCalibur cytometer (BD Bio-
sciences) and analyzed using FlowJo software (Tree Star, San Carlos, CA).
Biofilm formation and desiccation experiments
Biofilm formation in a rich-medium condition (LB) was determined and visualized as previ-
ously described [25]. Colony morphology and color on Congo red agar plates were tested after
48 hours of incubation at 28°C [29].
The desiccation experiment was adapted from a described protocol [30]. Briefly, 100 μl
from overnight cultures grown in LB medium at 37°C were tested immediately (initial num-
bers) or air dried and stored in 24 well tissue culture plates at room temperature for 12 days.
After rehydration of bacteria in 500 μl PBS, pH 7.4, the number of viable cells remaining in
each sample was determined by serially diluting cell mixtures and plating in duplicate. The
experiment was conducted in triplicate.
Production of recombinant SEN4316
The sen4316 gene was amplified from wild type genomic DNA with primers sen4316 BamHI-
fw (ggatccatgacaacaccatcctggcg) and sen4316 SalI-rv (gtcgactcatagggcgcgcatgtcgt), using Phu-
sion High-Fidelity DNA Polymerase (Fermentas-Thermo Scientific). The PCR-amplified frag-
ment was cloned in pGEM-T Easy (Promega), sequenced and digested with BamHI and SalI to
clone it into the pET28a vector (Novagen). The resulting plasmid pET28a::sen4316 was electro-
porated into E. coli BL21 C43 (DE3) [31]. Cultures were grown at 37°C, 250 rpm, to an optical
density (OD600) of 0.5, and isopropyl-D-thiogalactopyranoside (IPTG) was added to a final
concentration of 0.4 mM. Cells were then grown overnight at 23°C. Harvested cells were lysed
with BugBuster HT Protein Extraction Reagent (Merck Millipore). SEN4316 accumulated in
inclusion bodies was obtained by centrifugation and suspension of insoluble material in CTAB
1%, incubation at room temperature for 1 h and recovery of the supernatant by centrifugation
at 20,000 x g. This supernatant was dialyzed against binding buffer (20 mM sodium phosphate,
500 mM NaCl, 20 mM imidazole, pH 7.4) and the recombinant protein was purified with a His
GraviTrap affinity column according to standard protocols (GE Healthcare). Eluted protein
was dialyzed against sterile water, analyzed by SDS–PAGE and Western-Blot and lyophilized.
SEN4316 based ELISA
Groups of ten mice were orally inoculated with a single dose of 107 cfu or 104 cfu of ΔXIII or
the wild type strain, respectively. Blood samples from the orbital vein of each mouse were col-
lected before inoculation and 33 and 44 days after inoculation. Samples were centrifuged and
sera from each group were collected and pooled. Nunc Maxisorp 96-well plates (Thermo Fisher
Scientific, San Jose, CA) were coated with SEN4316 (2 μg/well) in carbonate-bicarbonate buffer
(pH 9.6) and incubated at 4°C overnight. Plates were then washed three times with PBS-T and
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blocked with 5% nonfat dried milk powder in PBS-T at room temperature for 2 h. After three
washes with PBS-T, 100 μl of pooled sera diluted 1:100 in PBS-T containing 2.5% of BSA were
added to each well and incubated at room temperature for 2 h. Wells were washed three times
with PBS-T and 100 μl of horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG, IgM
(H+L) secondary antibody diluted 1:1250 (Thermo Scientific) was added to each well. The
plates were incubated for 2 h at room temperature and then washed three times. One hundred
microliters of ABTS (Sigma-Aldrich) were added to each well and the absorbance at 420 nm
was determined on an ELISA reader.
sen4316 PCR to differentiate vaccinated from infected mice
Faecal samples from the wild type and ΔXIII infected groups were pooled and collected at day
1, 7, 14 and 21 post-infection. Cages were cleaned daily to remove non collected faeces. DNA
from stool was extracted using a QIAamp DNA Stool Mini Kit (Qiagen). Oligonucleotides
DIVA-1 (cacgattacgccaactcgagttgt) and DIVA-2 (gtaagataactgtgcgaag) were used to amplify a
632 bp fragment from ΔXIII DNA. Amplification of invA with oligonucleotides invA-fw
(ggcgatattggtgtttatgg) and invA-rv (catattatcgctatcgccat) was used to amplify a 658 bp fragment
from wild type and ΔXIII DNA. The PCR amplification conditions were as follows: 1 cycle at
95°C for 5 min; 30 cycles of the following: 94°C for 30 s, 54°C for 30 s and 72°C for 35 s; 1 cycle
of 72°C for 7 min.
Statistical analyses
All statistical analyses were performed in GraphPad Prism 5.01. A Log-rank (Mantel-Cox) test
was used to assess significance in mice survival assays. A Wilcoxon signed-rank test was used
to determine whether the CI values were significantly different from the hypothetical value of
zero. A two-way analysis of variance combined with the Bonferroni test was used to analyze
statistical significance in antibody titers, cytokine serum levels and data from flow cytometry
assays. A nonparametric Mann-Whitney test was used to assess significant differences in the
opsonization assay. Differences in cytokine production in splenocytes assayed by ELISPOT
and ELISA were determined using the unpaired Student’s t test.
Results
Analysis of the contribution of c-di-GMP signaling to Salmonella
virulence
To evaluate the impact of the absence of c-di-GMP on Salmonella virulence, we firstly com-
pared the survival rates of groups of seven BALB/c mice, which are susceptible to systemic
infection with Salmonella, orally infected with 107 cfu of the wild type S. Enteritidis strain 3934
or its derivative, new ΔXII strain. ΔXII showed virulence attenuation that manifested by a latter
time to death than animals infected with wild type Salmonella. However, the difference
between survival curves was no statistically significant (p = 0.2287) and at the end of the exper-
iment ten and twenty percent of mice survived after infection with the wild type and ΔXII
respectively (Fig 1A). Virulence of ΔXII after infection by the natural oral route was further
investigated by carrying out a competitive index (CI) analysis in an ileal loop coinfection exper-
iment and also, by assessing the level of organ colonization following oral co-inoculation of the
wild type and ΔXII strains. ΔXII showed a significantly reduced capacity to adhere and invade
the intestinal epithelium (Fig 1B) and a significantly lower ability to colonize livers and spleens
of orally infected mice (Fig 1C). Defectiveness of ΔXII colonization at systemic sites was addi-
tionally confirmed by evaluating organ colonization after intraperitoneal (i.p) infection. ΔXII
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mutant colonized both the spleen and liver of i.p infected mice significantly less than the wild
type strain (Fig 1D). Taking together, these results showed that c-di-GMP signaling is required
for natural virulence of Salmonella in BALB/c mice, since absence of c-di-GMP rendered bacte-
ria significantly less able to adhere and invade the intestinal epithelium and to colonize sys-
temic organs during acute infection. However, the overall outcome of the lack of c-di-GMP
signaling in pathogenicity is subtle, resulting in a non significant virulence attenuation.
Construction and virulence characterization of a Salmonella strain
lacking all GGDEF proteins and the RpoS sigma factor
Results described above carried out with new ΔXII strain, which only lacks GGDEF proteins
encoding genes, demonstrated that absence of c-di-GMP has a restrained impact on virulence.
Fig 1. c-di-GMP signaling in Salmonella is required for intestinal epithelium and organ colonization of
BALBcmice but its absence does not significantly affect BALBcmice survival. (A) Comparative lethality
between wild-type (black circles) and ΔXII (black squares) strains in an oral infection mouse model. Inoculum
administered was 107 cfu/mouse. P-value was determined by a Log-rank (Mantel-Cox) test. ns; no significant
difference. (B) Competitive index (CI) analysis of wild type and ΔXII strains after performing an ileal loop coinfection
experiment. Nine ileal loops were coinfected with 2x107 cfu containing equal numbers of the parental and ΔXII
strains. (C) CI analysis following intragastric inoculation of ten BALBc mice with a 1:1 mixture of wild type and ΔXII
strains (total inoculum administered was 2 x 108 cfu). Mice were sacrificed after five days and bacteria were
enumerated from livers and spleens. (D) CI analysis following intraperitoneal inoculation of seven BALBc mice with
a 1:1 mixture of wild type and ΔXII strains (total inoculum administered was 2 x 104 cfu). Mice were sacrificed three
days postinoculation and bacteria were enumerated from livers and spleens. CI was defined as the log10 of the ratio
of wild type strain to ΔXII strain recovered (Output) divided by the ratio of wild type strain to ΔXII strain present in
the inoculum (Input). A CI > 0 indicates wild type with a colonization advantage compared to ΔXII and a CI < 0
indicates wild type with a colonization disadvantage over ΔXII. The plots display values obtained from individual
samples and the median CI is represented by horizontal bars. P-values were determined by aWilcoxon signed-
rank test. *P < 0.05; ** P < 0.01; *** P < 0.001.
doi:10.1371/journal.pone.0161216.g001
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On the other hand, the firstly described ΔXII strain, that also contains a chromosomal deletion
that includes the rpoS gene, is completely avirulent in mice [16]. Hence, we next wondered
whether this avirulent phenotype was solely caused by the absence of RpoS or by the synergic
effect of the lack of RpoS and c-di-GMP. To analyze this, we compared the pathogenic behavior
of the wild type strain, a single rpoSmutant, and a derivative of new ΔXII strain in which we
deleted the rpoS gene. This novel mutant was named ΔXIII. A survival experiment of orally
infected BALB/c mice with 107 cfu of each strain showed that, in agreement with our previous
results, ΔXIII strain exhibited a total attenuated behavior and thus, all mice infected with this
strain survived at day 28 and did not present any morbid symptoms (Fig 2A). In contrast, the
survival rate of mice infected with the wild type strain was only 10% at the end of the experi-
ment, whereas infection with the rpoSmutant rendered a final survival of 60% of infected mice
(Fig 2A). To certify virulence loss of ΔXIII, mice inoculated with this strain were sacrificed at
the end of the experiment and a complete clearance of infection was confirmed by the absence
of Salmonella in livers, spleens and faeces.
Since a Salmonella vaccine strain needs to be invasive enough to induce durable immunity
in the host and thus, an excessive attenuation of ΔXIII strain was not desirable, we tested its
invasiveness capacity at an earlier time of infection. For that, we orally infected groups of seven
BALB/c mice with 2x107 cfu of a 1:1 mixture of the wild type and ΔrpoS or ΔXIII strains. At
day 7 post infection, animals were euthanized, bacterial load in spleens was determined and the
CI was calculated. As shown in Fig 2B, ΔXIII was capable of reaching and colonizing internal
organs, although, when compared to the wild type strain, it presented an approximately 104
fold defect in its ability to colonize spleens of infected mice. Again, ΔrpoSmutant exhibited an
intermediate attenuation phenotype, confirmed by a 102 deficiency in spleen colonization.
Altogether, these data show that in ΔXIII strain, the absence of both c-di-GMP signaling
and the sigma factor RpoS exerts a synergistic attenuating effect on Salmonella virulence, that
turns this novel mutant strain into a potential live attenuated vaccine.
Evaluation of the protection conferred by vaccination with ΔXIII
With the aim of investigating the efficacy of ΔXIII strain as an orally administered vaccine
against salmonellosis, a vaccination-challenge analysis was carried out in BALBc mice, using a
Fig 2. The synergic effect of the absence of RpoS and c-di-GMP signaling in ΔXIII strain results in high
virulence attenuation. (A) Comparative lethality between wild-type (black circles), ΔrpoS (black triangles) and
ΔXIII (open squares) strains in an oral infection mouse model. Groups of ten mice were orally infected with 107 cfu/
mouse. P-values were determined by a Log-rank (Mantel-Cox) test. (B) CI analysis following intragastric
inoculation of seven BALBc mice with a 1:1 mixture of wild type and ΔXIII or ΔrpoS strains (total inoculum
administered was 2 x 107 cfu). Mice were sacrificed after seven days and bacteria were enumerated from spleens.
CI for the wild type and mutant strains was defined as stated in Fig 1 legend.
doi:10.1371/journal.pone.0161216.g002
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clinical isolate of S. Typhimurium as the challenge strain. The reason why this strain was used
for challenge is that, according to the report of the European Food Safety Authority (EFSA) for
the year 2014 (https://www.efsa.europa.eu/en/efsajournal/pub/4329), S. Enteritidis and S.
Typhimurium are the two most commonly reported serovars in confirmed human cases.
Moreover, S. Enteritidis is the second most commonly reported serovar from broiler meat and
S. Typhimurium is the most frequently reported serovar in pigs and cattle and also in pig meat.
By using S. Typhimurium for challenge we assessed both ΔXIII vaccination efficacy and also
the level of cross-protection against other Salmonella serovar. Groups of 7 mice were orally
immunized with a single dose of 107 cfu of either the ΔXIII or ΔrpoS strain. This last strain was
used as an immunizing control. A third group of mice was given 100 μl of sterile PBS. Vacci-
nated and control untreated mice were challenged 33 days post immunization with 106 cfu (10
fold the LD50) of S. Typhimurium 143/09 and data on number of dead mice were daily col-
lected. As shown in Fig 3, all non vaccinated animals died within a 10 day period post chal-
lenge. In contrast, 90% of ΔXIII immunized mice survived after challenge. Vaccination with
ΔrpoS resulted much less effective, firstly because, according to the results presented above,
30% of mice died before challenge, and secondly, because, after challenge, only 30% of initial
mice remained alive. These results demonstrated that immunization with ΔXIII confers a very
significant degree of crossprotection against salmonellosis by S. Typhimurium in mice.
Characterization of the immune response generated by immunization
with ΔXIII strain
While performing the vaccination experiments described above, and in order to know the basis
of the protection conferred by ΔXIII, serum from mice of the control and ΔXIII immunized
Fig 3. Vaccination-challenge analysis of the protection conferred by ΔXIII.Groups of seven BALBc mice were
orally vaccinated with 107 cfu of ΔXIII (open squares), ΔrpoS (black triangles) or PBS as a control (black circles). 33
days post immunization, mice were challenged with 106 cfu/mouse of S. Typhimurium 143/09. Survival curves were
plotted and P-values were determined by a Log-rank (Mantel-Cox) test.
doi:10.1371/journal.pone.0161216.g003
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groups were collected right before immunization and 14 and 28 days after immunization. An
ELISA assay was then carried out to measure the levels of IgG and IgM against a ΔXIII heat-
killed lysate in individual sera. Results showed a very significant antibody response in mice
immunized with ΔXIII strain when compared to control mice, treated with PBS (Fig 4A).
Then, pooled sera samples were used to examine the efficiency of such generated antibodies to
promote opsonization and phagocytosis of S. Typhimurium 143/09 by J774.2 murine macro-
phage cells. As shown in Fig 4B, the number of phagocytized bacteria was significantly higher
when bacteria were preincubated with 10% of sera from ΔXIII immunized animals than when
incubated with preimmune sera. The specificity of these antibodies against Salmonella was con-
firmed by the fact that the uptake of bacteria preincubated with preimmune sera was very simi-
lar to the uptake of bacteria suspended in PBS (relative bacterial uptake close to one).
Since both humoral and cellular responses are necessary for immunity to oral challenge
with virulent S. Typhimurium [7], we next determined serum levels of IFN-γ (a prototype Th1
cytokine), as well as IL-10 and IL-5 (prototype Th2 cytokines). Remarkably, significant IFN-γ
and IL-10 levels were detected in pooled sera from ΔXIII immunized animals and not from
PBS treated mice (Fig 5A). In particular, 14 days after immunization, IL-10 levels in sera from
ΔXIII immunized mice were much higher than in sera from control mice (p<0.001). These lev-
els decreased over time, although 28 days after immunization, they were still significantly
higher than in control sera (p<0.01). As regards IFN-γ, it was also significantly present in sera
from ΔXIII immunized mice (p<0.05) collected 14 and 28 days after immunization. On the
other hand and in the case of IL-5, it is important to note that this cytokine was barely detect-
able in all samples analyzed.
Fig 4. Humoral immune responses in mice immunized with ΔXIII strain. A) Sera obtained 14 and 28 days
post-immunization frommice immunized with ΔXIII present significantly higher levels of IgG and IgM against heat-
killed ΔXIII bacteria than sera from non immunized mice (control, treated with PBS) as determined by ELISA. No
antibody to heat-killed ΔXIII bacteria was detected in sera from control mice (reciprocal titer, <1:20). Error bars
represent standard deviation between individual antibody titers. Statistical analysis was carried out using a two-
way analysis of variance combined with the Bonferroni test. *** P < 0.001. B) Opsonization with immune serum
enhances the uptake of Salmonella by murine macrophage cells. Opsonization and phagocytosis of S.
Typhimurium143/09 by J774.2 macrophages was tested by counting the number of phagocytosed bacteria that
had been previously mixed with 10% immune serum obtained 28 days post immunization (IM), pre-immune serum
(PreIM) or PBS. The relative bacterial uptake of bacteria mixed with serum with respect to the uptake of bacteria
suspended in PBS (value of 1.0) is represented. Results from duplicates on three separate days are shown.
Statistical analysis was performed using the Mann–Whitney test. *P < 0.05.
doi:10.1371/journal.pone.0161216.g004
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To confirm the results obtained from sera and to evaluate the ΔXIII specific stimulation of
cytokines production by spleen cells from immunized mice, we performed the following exper-
iments. Supernatants of stimulated splenocytes with 107 cfu of heat-killed ΔXIII bacteria were
analyzed for the production of IL-2 (prototype Th1 cytokines), IL-10 (prototype Th2 cyto-
kines), and the Th17-associated cytokine IL-17. Remarkably, levels of the three cytokines were
Fig 5. ΔXIII induced cellular immune responses. A) Sera from ΔXIII immunized mice present significantly higher levels of interferon gamma (IFN-
γ) and IL-10 than sera from the control group, treated with PBS. Quantification (pg/ml) of IFN-γ, IL-5 and IL-10 in pooled sera from the control group
(PBS) and from the ΔXIII immunized group was carried out using respective ELISA kits. Error bars represent standard deviation between duplicate
wells. Statistical analysis was carried out using a two-way analysis of variance combined with the Bonferroni test. ns = no significant difference;
*P < 0.05; ** P < 0.01; *** P < 0.001. B) ΔXIII immunization induces production of cytokines in splenocytes. 28 days postimmunization, splenocytes
were harvested from control and ΔXIII immunized mice and restimulated for 48 h with 107 cfu of heat-killed ΔXIII bacteria. RPMI media was used as a
non-stimulating control. Cell supernatants were harvested and analyzed for IL-2, IL-10 and IL-17 production using respective ELISA kits. Statistical
analysis was carried out using the unpaired Student t test. C) Numbers of IFN-γ producing cells in spleens from control and ΔXIII immunized mice
were determined by ELISPOT assay. Splenocytes were harvested from all mice at 28 days after immunization. The results are expressed as spots
per million splenocytes minus background from cells stimulated with 107 cfu of heat-killed ΔXIII bacteria. Each point represents an individual mouse.
Lines indicate the mean of the replicates. Significant differences between groups are indicated and were determined using the unpaired Student t
test. *** P < 0.001. D) CD4+ T cells produce IFN-γ and TNF-α upon ex vivo re-stimulation following vaccination with ΔXIII. 28 days after
immunization, splenocytes from control and ΔXIII immunized mice were plated and stimulated for 6 hours with medium, 106 or 107 cfu of heat-killed
ΔXIII bacteria. Cells were surface stained with anti-CD4 and anti-CD8 mAbs and intracellularly stained with anti-IFN-γ and anti-TNF-α antibodies.
Shown are percentages of IFN-γ and TNF-α cells out of total CD4+ and CD8+ T cells. Each point represents an individual mouse. Lines indicate the
mean of the replicates. Significant differences between control and vaccinated groups are indicated and were determined using the unpaired Student
t test. ns = no significant difference; ** P < 0.01; *** P < 0.001.
doi:10.1371/journal.pone.0161216.g005
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significantly higher in supernatants from splenocytes of immunized mice than in supernatants
from splenocytes of control mice (Fig 5B). It is important to note that differences were higher
in the case of IL-2 and IL-17 production (p<0.001) than in the case of IL-10 (p<0.05). Also, an
ELISPOT assay was carried out to investigate IFN-γ production and results showed that splenic
lymphocytes from mice immunized with ΔXIII strain produced significantly more levels of
IFN-γ secreting T cells than those of control mice (p<0.001) (Fig 5C). Finally, we used flow
cytometry coupled with stimulations with heat-killed ΔXIII bacteria to measure IFN-γ and
TNF-α production by CD4 and CD8 T cells (Fig 5D and S1 Fig). A strong CD4 T cell response
specific of ΔXIII heat-killed bacteria was detected in AXIII immunized mice. Curiously, IFN-γ
and TNF-α production was not detected in CD8 T cells (Fig 5D, left). It is likely that the use of
heat-killed bacteria for the intracellular detection of cytokines might have hindered the accu-
rate analysis of the CD8 T cell response, since heat-killed bacteria are not efficiently processed
and presented by MHC-I molecules [32]. The assessment of the CD8 T cell response induced
by ΔXIII requires further work that involves the identification of bacterial antigens and/or the
use of recombinant bacteria expressing reporter antigens.
Overall, these data indicate that mechanisms underlying ΔXIII mediated protection include
the production of opsonizing antibodies and a mixed T cell response characterized by signifi-
cant levels of IFN-γ, TNF-α, IL-2, IL-17 and IL-10.
Evaluation of ΔXIII as a live DIVA vaccine
A Salmonella ideal vaccine must not interfere with control programs, in the sense that infected
animals with virulent field Salmonella strains must be differentiated from vaccinated animals.
Therefore, we next aimed at exploring the properties of ΔXIII strain as a DIVA (Differentiation
of Infected and Vaccinated Animals) vaccine. Since ΔXIII strain is a multiple mutant carrying
deletions in rpoS and also in all GGDEF domain proteins encoding genes, we investigated the
possibility of using the absence of one GGDEF protein as a DIVA marker. Interestingly, the
GGDEF domain protein encoding gene sen4316 does not show any orthologous gene in other
enterobacteriaceae and thus, we found conceivable the idea of using the antibodies raised
against this protein, that could only be developed in animals that had been colonized by a natu-
ral wild type strain but would be absent in vaccinated ones, in order to differentiate infected
and vaccinated individuals. To prove so, groups of 10 mice were orally inoculated with a single
dose of 107 cfu of ΔXIII or a sublethal dose (104 cfu) of the wild type strain and sera samples
were obtained periodically up to day 44 post inoculation. Concurrently, we designed a specific
ELISA assay in which a 6-His–tagged recombinant version of SEN4316 was used as the bound
antigen. This assay showed that titers of antibodies against SEN4316 in pooled sera from ani-
mals infected with the wild type strain rose gradually after infection. On the contrary, and as
expected, titers in pooled sera proceeding from ΔXIII immunized animals remained negative
(Fig 6A).
In addition to the immunoassay, we also explored the possibility of using the sen4316 gene
as a positive genetic marker to identify vaccinated animals through PCR. To do so, faecal sam-
ples from each group were pooled and collected periodically and bacterial genetic material was
extracted. Oligonucleotide DIVA-1 was designed so that the 5´end of the oligonucleotide
hybridizes to a DNA sequence downstream sen4316 whilst the 3´end of the oligonucleotide
hybridizes to a DNA sequence upstream sen4316 (Fig 6B). Oligonucleotide DIVA-2 hybridizes
to a DNA sequence downstream sen4317 (Fig 6B). PCR conditions were designed in such a
way that amplification only took place if the ΔXIII genome acted as template DNA. On the
other hand, amplification of the Salmonella specific gene invA with oligonucleotides invA-fw
and invA-rv was used as an internal positive control in all samples. Faecal samples proceeding
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from animals infected with the wild type strain resulted invA positive, DIVA negative, while
samples proceeding from vaccinated animals resulted invA positive, DIVA positive (Fig 6B).
These results confirmed that ΔXIII can be considered a DIVA vaccine since the GGDEF
protein SEN4316 enables discrimination of vaccinated animals either by immunological or by
molecular non sophisticated approaches.
Survival of ΔXIII in the environment
One important drawback of live attenuated vaccines is that the strain, once excreted by vacci-
nated animals, may persist for long periods in the environment. To determine whether this
might be a handicap to the use of ΔXIII strain, phenotypic traits involved in environmental
persistence, such as resistance to desiccation in the absence of nutrients and biofilm formation
were assessed.
Results showed that almost 100% of wild type bacteria remained viable after 12 days under
waterless conditions. On the contrary, both ΔrpoS and ΔXIII strains showed to be dramatically
sensitive to desiccation, since, at the end of the experiment, there were not any live bacteria left
(Fig 7A). Biofilm formation capacity was analyzed by incubating bacteria in LB broth under
static and room temperature conditions for 72 hours and also, by analyzing colony morphology
on plates containing the Congo Red dye (Fig 7B). ΔrpoS and ΔXIII strains did not form a bio-
film in LB and showed a “saw” (smooth and white) morphotype, which corresponds with the
inability to produce cellulose and fimbriae, the main components of the Salmonella biofilm
matrix, and thus a total absence of multicellular behavior.
Fig 6. ΔXIII is a DIVA vaccine that allows differentiation of infected and vaccinated animals. (A) SEN4316 based ELISA of
pooled sera from wild type and ΔXIII infected animals, obtained before infection (PreIM) and 33 and 44 days post infection. Sera
from animals infected with the wild type strain and not with ΔXIII present antibodies against the SEN4316 protein. Error bars
represent standard deviation between triplicate wells. (B) DNA from pooled faecal samples from wild type and ΔXIII infected
animals, collected at day 1, 7, 14 and 21 post infection, were analyzed by PCR. Amplification of stool DNA with primers DIVA-1 and
DIVA-2 allowed the identification of vaccinated animals with ΔXIII strain. Amplification with primers invA-fw and invA-rv served as a
control of the presence of Salmonella DNA. Results shown are representative of results obtained throughout time, since Salmonella
DNA was present in faecal samples since day one post infection.
doi:10.1371/journal.pone.0161216.g006
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These results demonstrate that ΔXIII might be easily eliminated from the environment
when excretion by vaccinated animals occurs.
Discussion
C-di-GMP is recognized as a universal bacterial second messenger implicated in the regulation
of a large number of cellular functions, including cell cycle progress, differentiation, biofilm
formation and dispersion, motility and virulence. As regards virulence, it is generally assumed
Fig 7. ΔXIII strain is unable to form a biofilm and does not survive after twelve days of desiccation in the
absence of nutrients. (A) Survival of the wild type strain, new ΔXII (absence of c-di-GMP), the single ΔrpoS
mutant and the vaccine candidate ΔXIII after twelve days of desiccation. Surviving bacteria were enumerated by
viable plate counts, and their numbers were compared with those of initial inocula, which defined 100% survival.
Means and standard deviations of results from three independent experiments are shown. (B) Biofilm formation
capacity of the same strains. Biofilm phenotypes were visualized after growth in LB medium conditions and on
congo red agar plates.
doi:10.1371/journal.pone.0161216.g007
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that high levels of c-di-GMP in bacterial cells promote biofilm formation and the establishment
of chronic infections, whilst low c-di-GMP levels promote virulence factor synthesis and thus,
acute infections [17,33,34]. In contrast to this general view, our results with new ΔXII strain,
which lacks all GGDEF domain proteins and thus cannot make c-di-GMP, have demonstrated
that, in Salmonella, absence of c-di-GMP signaling is detrimental for the development of an
acute infection. Virulence decrease shown by ΔXII strain was subtle but consistent enough to
indicate that either an specific GGDEF domain protein or a certain c-di-GMP related pheno-
type or c-di-GMP itself might be required at some stage of the Salmonella acute infection.
These results are in line with recent evidences that are revealing a more complicated picture
about the relationship of the c-di-GMP network and virulence than expected. Individual
mutants in not only c-di-GMP degrading enzymes (phosphodiesterases; PDEs) but also syn-
thesizing enzymes (diguanylate cyclases; DGCs) have shown to display attenuation in infection
models [35–37], suggesting that opposite c-di-GMP-metabolizing processes might play a role
at different disease stages [17]. Also, putative DGCs and PDEs with no c-di-GMP metabolizing
activity have been described to affect virulence [38–42]. Accordingly, virulence defect of ΔXII
strain might be explained by the fact that several Salmonella GGDEF domain proteins harbor a
degenerated consensus signature and might somehow control virulence independently of c-di-
GMP levels. With respect to the participation in virulence of a particular c-di-GMP controlled
phenotype, we showed in a previous study that production of cellulose is not involved in the
virulence of S. Enteritidis in BALB/c mice infected orally or intraperitoneally [25]. However, a
very recent report by Pontes et al. [43] has demonstrated that Salmonellamakes cellulose inside
macrophages and that its synthesis hinders Salmonella replication inside host cells. Thus, a cel-
lulose mutant strain was hypervirulent in C3H/HeN mice injected intraperitoneally. In any
case, results of both studies do not correspond with results obtained here which show that ΔXII
strain, that cannot synthesize cellulose, is less virulent than the wild type strain. Hence, viru-
lence defect of ΔXII strain cannot be attributed to a lack of cellulose synthesis. With regard to
the direct contribution of c-di-GMP to virulence, it is known that it binds to the eukaryotic
proteins STING and DDX41 [18–21], leading to induction of type I interferons and thus,
apparently contributing to successful pathogen elimination. This fact, again, does not agree
with ΔXII strain being less virulent than the wild type strain. On the contrary, ΔXII virulence
attenuation might be related to a very recent research of Li et al. [44] finding that c-di-GMP
directly binds to human siderocalin (LCN2). LCN2 sequesters bacterial siderophores to prevent
iron acquisition and inhibit bacterial growth under iron-limited conditions [45,46]. Li et al.
showed that c-di-GMP competes with bacterial siderophores to bind to LCN2, therefore, pre-
venting LCN2 from inhibiting bacterial growth. These results indicated that c-di-GMP inter-
feres with LCN2 to ensure bacterial survival during infection and that inhibition of c-di-GMP
production should attenuate virulence. Further detailed analysis of the contribution of the c-
di-GMP signaling network to Salmonella virulence will be required to figure out the reasons
why ΔXII strain presents an attenuated phenotype.
Once we cleared up the effect of the absence of c-di-GMP signaling in Salmonella virulence,
and with the final aim of constructing a novel vaccine candidate, we performed a mutation of
the rpoS gene in ΔXII, giving rise to strain ΔXIII. Absence of all GGDEF domain proteins and
also of RpoS had a synergistic attenuating effect that made ΔXIII extremely safe and capable to
protect vaccinated mice from a lethal dose challenge of a wild type S. Typhimurium strain. The
cross-talk between T and B cells is of fundamental importance for the establishment of solid
acquired immunity to salmonellosis [8]. Accordingly, mice protection with ΔXIII strain was
found to occur via different immune responses including Salmonella-specific IgGs that showed
a moderate opsonic activity and high levels of the pro-inflammatory cytokines IFN-γ, TNF-α,
IL-2, IL-17 and also of the anti-inflammatory cytokine IL-10. IFN-γ has a crucial role for
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clearing infections caused by intracellular bacteria, given that its major effect is macrophage
recruiting and that activation and high titters of this cytokine generally implies a strong
immune response that is accompanied by T-lymphocyte expansion [47,48]. Thus, mice treated
with anti-IFN-γ antibodies and also, mice and humans genetically deficient in immunity medi-
ated by IFN-γ are highly susceptible to Salmonella [49–51]. With respect to IL-17, it is emerg-
ing as a central element of mucosal immunity to microbial challenge since it enhances basic
innate barrier defenses such as antimicrobial peptide production and neutrophil recruitment
[52]. Accordingly, S. Typhimurium-infected IL-17-receptor-A-deficient mice have lower
amounts of inflammatory cytokines, less neutrophil recruitment and increased bacterial trans-
location to the spleen and mesenteric lymph nodes [53]. On the other hand, IL-10 is a well-
characterized anti-inflammatory cytokine that inhibits synthesis of Th1 cytokines and prolifer-
ation of T cells, preventing the detrimental consequences of systemic inflammation [54]. The
presence of IL-10 in ΔXIII immunized animals suggests that the immune response was tightly
balanced [55,56] and that ΔXIII might exploit the immunosupresive effects of IL-10 to persist
in mice organs, eliciting a long-lasting immunity [57].
Up to date there is no ideal vaccine available for control of salmonellosis in farm animals.
Such a vaccine should be cheap, minimally reactive and preferably live and invasive but still
safe to induce strong immunity [58]. Furthermore, the use of attenuated vaccines as veterinary
drugs can only be recommended if differentiation of vaccinated from infected animals (DIVA)
is feasible in a basic bacteriology laboratory [58,59]. In response to this need, antigenic, genetic
and phenotypic markers have been incorporated into or eliminated from attenuated vaccines
[60,61]. However, bacterial “tagging” is normally achieved through genetic engineering meth-
ods and serious concerns are being raised about the effects that genetically modified microbes
(GMMs) may have if massively used or released into the environment [62]. In order to avoid
the use of antibiotic markers, ΔXIII strain is the result of thirteen consecutive deletion steps in
which an allelic exchange strategy with sacB as the counterselectable marker was used [16,22].
Thus, ΔXIII does not contain any trace of exogenous DNA and is indistinguishable from a nat-
urally occurring mutant, fact that eludes its classification as a GM organism according to the
European Directive [EC] 2001/18. Amongst the thirteen candidates to become a negative
selectable marker, we found several reasons for choosing the GGDEF protein SEN4316. In con-
trast to other GGDEF proteins, SEN4316 is conserved in all S. enterica serovars and thus, it can
be considered a “broad spectrum”marker since seroconversion is likely to occur upon infection
of animals with any Salmonella serovar, thereby activating the DIVA function [59]. On the
other hand, E. coli and other gram negative species lack this member of the GGDEF family
(data not shown). We designed a SEN4316 based ELISA that allowed the serological discrimi-
nation of vaccinated from infected mice. In addition, and since such DIVA strategy identifies
infected animals, we developed a very simple molecular method to positively identify vacci-
nated animals. However, its application would be restricted to the period of time in which the
vaccine is present in faeces.
Because live vaccines can be potentially excreted into the environment by immunized ani-
mals, another condition of increasing interest in vaccine development is the easiness to elimi-
nate it from the environment [3,63]. Undoubtedly, this is one of the strengths when
considering ΔXIII strain as a live vaccine candidate since it is totally incapable of synthesizing a
protective biofilm matrix and lacks RpoS, a regulator that is indispensable to mount an ade-
quate response against environmental stresses. Accordingly, less than two weeks were sufficient
to end up with 100% of ΔXIII bacteria under waterless conditions.
Salmonellamutants of reduced virulence that still display high immunogenicity have
already been described [3–5,10]. We propose that the c-di-GMP signaling and RpoS defective
Salmonella strain described here, which shows a delicate safety-immunogenicity balance,
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promising DIVA features and can be easily eliminated from the environment is a noticeable
new candidate to include in this list. Future work will be conducted to analyze its potential use
in field vaccination trials.
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